法乐通治疗晚期乳腺癌临床总结

目的 考察法乐通治疗晚期绝经后乳腺癌的放疗及其不良反应。方法：法乐通一线治疗每日一次６０ｍｇ口服，二线治疗每日一次１２０ｍｇ口服。结果：共６０例，有效率１８．３％，一线治疗１８例，有效率３３．３％，二线治疗４２例，有效率１１．９％，淋巴结和骨转移疗效较好，肝转移，肺转移及胸壁转移也有一定疗效。一线治疗较二线治疗，未用内分泌治疗较曾用内分泌治疗，绝经时间长（≥１０年）较经时间短（〈１０年）以及疗后无

Clinical trial of toremifene in postmenopausal patients with advanced breast cancer

Objective: To observe the efficacy and toxicities of toremifene in postmenopausal patients with advanced breast cancer. Methods: From September 1996 to March 1998,60 postmenopausal patients with advanced breast cancer were enrolled in this study.Toremifene(TOR)has been assessed both as initial(firstline)and secondline treatment following failure of other measures such as hormonal treatment and/or cytotoxic chemotherapy.The patients with firstline were assigned to receive daily 60 mg TOR.The patients with secondline were assigned to receive daily 120 mg TOR. Results: The overall response rates(complete response and partial response)was 183%in all patients.The overall response rate was 333%in 18 patients as firstline treatment.The overall response rate was 119%in 42 cases patients as secondline treatment.The response rates of lympohatic and bone metastases were higher.The response rates inpatients with firstline treatment,no prior hormone treatment and longer menopausal time(10 years) were higher than that in patients with secondline treatment,prior hormone treatment and shorter menopausal time(< 10 years)(not statistically different).The response rates in patients with longer diseasefree interval(5 years) were higher than that in patients with shorter disseasefree interval(< 5 yeays)(statisically dlifferent).The most common adverse effects were nause and anorexia. Conclusion: TOR was an effective and safe antiestrogens and antiumor agent in postmenopausal patients with advanced breast cancer.